Atlas Trials

A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521

Clinical trial NCT05323045 · COMPLETED

Trial details

NCT number
NCT05323045
Sponsor
Byondis B.V.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumor
Start date
2022-03-21
Primary completion
2024-03-04
Enrollment
31

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.